Aurobindo Pharma Shares Decline 4% After US FDA Cites Lapses at Unit-7
Loading more articles...
Aurobindo Pharma Shares Plunge 4% After US FDA Flags Lapses at Unit-7
C
CNBC TV18•18-02-2026, 11:46
Aurobindo Pharma Shares Plunge 4% After US FDA Flags Lapses at Unit-7
•Aurobindo Pharma shares dropped 4% following US FDA's Form 483 observations for its Unit-7 facility.
•The FDA inspection from January 28 to February 10, 2026, revealed multiple manufacturing and quality control lapses.
•Key issues included unclean equipment, inadequate computer system controls, deficient master manufacturing records, and poor complaint handling.
•A serious observation noted a microbiologist allegedly falsifying sample collection data, raising data integrity concerns.
•Analysts are divided, with some fearing an OAI or Warning Letter due to data integrity issues, while others see observations as procedural, expecting VAI.
